Aims & Scope – Current Pharmaceutical Biotechnology

Aims & Scope

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:

  • DNA/protein engineering and processing
  • Synthetic biotechnology
  • Omics (genomics, proteomics, metabolomics and systems biology)
  • Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
  • Drug delivery and targeting
  • Nanobiotechnology
  • Molecular pharmaceutics and molecular pharmacology
  • Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
  • Pharmacokinetics and pharmacodynamics
  • Applied Microbiology
  • Bioinformatics (computational biopharmaceutics and modeling)
  • Environmental biotechnology
  • Regenerative medicine (stem cells, tissue engineering and biomaterials)
  • Translational immunology (cell therapies, antibody engineering, xenotransplantation)
  • Industrial bioprocesses for drug production and development
  • Biosafety
  • Biotech ethics

Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.

Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.

 

cpb-flyer

 

For more details, please visit: https://benthamscience.com/journals/current-pharmaceutical-biotechnology/aims-scope/#top

Press Release for EurekAlert! Zebrafish as an animal model to study the effects of endocrine disruptors

zebra-fish

Water is vital for our survival. However, water quality is always a concern for public health authorities as it may contain diverse environmental pollutants, including endocrine disrupting chemicals (EDCs). Endocrine disrupting chemicals are one group of potentially hazardous substances that comprise natural and synthetic chemicals, with the ability to mimic endogenous hormones or interfere with their biosynthesis, metabolism, and normal functions. Common examples are bisphenol A, triclosan, phthalates, lead, mercury, nickel and polychlorinated biphenyls, among others.

Fish are known to be quite sensitive to the effects of EDCs and therefore, are employed as research models to study the possible impacts of these chemicals in humans. In a review led by Purdue University (USA) and the University of Cartagena (Colombia), a team of researchers has proposed the zebrafish as a model to predict the effects of EDCs on humans using toxicogenomic tools, such as microarrays or whole-genome sequencing. This is possible due to the fact that zebrafish genes that have significantly altered expression after exposure to EDCs are very similar to those found in humans. In addition, many of the glandular system found in zebrafish have similarities with those in humans, making this fish model suitable to study alterations on the endocrine system.

According to the authors, vitellogenin and aromatase cytochrome P450 are key genes that can be monitored in zebrafish to detect the presence of EDCs in water samples, especially at environmentally relevant concentrations.

Toxicogenomic tools also offer the possibility to find new mechanisms by which EDCs alter the reproductive status of zebrafish, allowing its use to test the safety of new products entering the market. The possibilities are immense and the goal is to continue finding new markers of toxicity, and therefore alternative bridges to link EDC exposure to common diseases in humans.

Co-authors of the paper include Karina Caballero-Gallardo, Jesus Olivero-Verbel (University of Cartagena, Cartagena, Colombia) and Jennifer L. Freeman (Purdue University, USA).

Reference: Caballero-Gallardo, K.; et al (2016). Toxicogenomics to Evaluate Endocrine Disrupting Effects of Environmental Chemicals Using the Zebrafish Model., DOI: 10.2174/1389202917666160513105959

For more information about the article, please visithttp://benthamscience.com/journals/current-genomics/volume/17/issue/6/page/515/

%d bloggers like this: